Category : Search result: Rybelsus

Novo Nordisk Alzheimer's trial fails, shares drop

Novo Nordisk's Rybelsus fails to slow Alzheimer's cognitive decline in major trial, causing a 10% share price drop. Read the full analysis of this pharmaceutical setback.